Favorable ECOG PS, lower LDH levels, and absence of BRAF and KRAS mutations at baseline were associated with long-term response to regorafenib in patients with mCRC in the real world.
Pashtoon Murtaza Kasi, MD, MS, discusses outcomes from an interim analysis of the BESPOKE CRC study and highlights the use of circulating tumor DNA for informing adjuvant chemotherapy treatment decisions for patients with stage II/III colorectal cancer.
Kohei Shitara, MD, discusses first-line nivolumab plus chemotherapy vs chemotherapy alone in gastric cancer, GEJ cancer, or esophageal adenocarcinoma.
Patients with unresectable hepatocellular carcinoma treated with regorafenib experienced more frequent serious TEAEs if they had Child-Pugh B liver function.
Pembrolizumab plus lenvatinib produced survival outcomes that were consistent with previous findings from the phase 3 LEAP-002 trial along with an extended duration of response.
Nivolumab plus chemotherapy improved PFS and OS vs chemotherapy alone in patients with advanced gastric, gastroesophageal junction, and esophageal cancers, according to 4-year data from the phase 3 CheckMate 649 study.
Eric Van Cutsem, MD, PhD, discusses primary efficacy and safety findings from the phase 3 SPOTLIGHT and GLOW trials investigating the monoclonal antibody zolbetuximab in metastatic gastric cancer.
Tumor treating fields concomitant with gemcitabine and nab-paclitaxel is being compared with chemotherapy alone in the frontline treatment of patients with aggressive, locally advanced pancreatic cancer as part of the phase 3 PANOVA-3 trial.